Evidence map›Paper›PMID 29610306›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Autochthonous tumors driven by

Samuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, Diana D Shi, Januka Khanal, Rebecca B Jennings, Jesse S Novak, Matthew G Oser, Alissa K Robbins, Rebecca Modiste and 8 more

Open access · bronzeAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Samuel K McBrayerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Benjamin A OlenchockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Gabriel J DiNataleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Diana D ShiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Januka KhanalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Rebecca B JenningsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Jesse S NovakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Alissa K RobbinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Rebecca ModisteLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210.
Dennis BonalLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210.
Javid MoslehiDivision of Cardiovascular Medicine, Department of Medicine, School of Medicine, Vanderbilt University, Nashville, TN 37235.
Roderick T BronsonDivision of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02215.
Donna NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Quang-De NguyenLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210.
Sabina SignorettiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Julie-Aurore LosmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215; william_kaelin@dfci.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USBrigham and Women's Hospital · USImaging Center · USVanderbilt University · US

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5M
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8M
Howard Hughes Medical InstituteNCI NIH HHS P50 CA165962NCI NIH HHS R35 CA210068
6 · The paper itself

Abstract

Inactivation of the retinoblastoma gene (

Indexed as

AllelesAnimalsDNA-Binding ProteinsEchocardiographyEnzyme ActivationFibroblastsGenes, RetinoblastomaHeart Septal DefectsHistone CodeIntegrasesJumonji Domain-Containing Histone DemethylasesMiceMice, Inbred C57BLMolecular Targeted TherapyNeoplasm ProteinsPituitary NeoplasmsCre recombinaseDNA-Binding ProteinsIntegrasesJumonji Domain-Containing Histone DemethylasesKdm5b protein, mouseNeoplasm ProteinsRecombinant Fusion ProteinsRetinoblastoma ProteinTamoxifencancerepigeneticsgenetically engineered mouse modelsJARID1AKDM5A

Identifiers

PMID29610306
PMCPMC5910822
OpenAlexW2795955102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.